Trajectories of change in depression severity during treatment with antidepressants
- 29 October 2009
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 40 (8), 1367-1377
- https://doi.org/10.1017/s0033291709991528
Abstract
Response and remission defined by cut-off values on the last observed depression severity score are commonly used as outcome criteria in clinical trials, but ignore the time course of symptomatic change and may lead to inefficient analyses. We explore alternative categorization of outcome by naturally occurring trajectories of symptom change. Growth mixture models were applied to repeated measurements of depression severity in 807 participants with major depression treated for 12 weeks with escitalopram or nortriptyline in the part-randomized Genome-based Therapeutic Drugs for Depression study. Latent trajectory classes were validated as outcomes in drug efficacy comparison and pharmacogenetic analyses. The final two-piece growth mixture model categorized participants into a majority (75%) following a gradual improvement trajectory and the remainder following a trajectory with rapid initial improvement. The rapid improvement trajectory was over-represented among nortriptyline-treated participants and showed an antidepressant-specific pattern of pharmacogenetic associations. In contrast, conventional response and remission favoured escitalopram and produced chance results in pharmacogenetic analyses. Controlling for drop-out reduced drug differences on response and remission but did not affect latent trajectory results. Latent trajectory mixture models capture heterogeneity in the development of clinical response after the initiation of antidepressants and provide an outcome that is distinct from traditional endpoint measures. It differentiates between antidepressants with different modes of action and is robust against bias due to differential discontinuation.Keywords
This publication has 35 references indexed in Scilit:
- Observational Research, Randomised Trials, and Two Views of Medical SciencePLoS Medicine, 2008
- Measuring depression: comparison and integration of three scales in the GENDEP studyPsychological Medicine, 2007
- Methodological Issues in Current Antipsychotic Drug TrialsSchizophrenia Bulletin, 2007
- Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approachesPharmaceutical Statistics, 2007
- Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant ActionArchives of General Psychiatry, 2006
- The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measuresEuropean Neuropsychopharmacology, 2006
- Application of pharmacogenetics to psychotic disorders: the first consensus conference1Participants (in alphabetical order): A. Breier, L.E. DeLisi, F. Henn, W. Kalow, R. Kerwin, J. Kurth, B. Lerer, A. Malhotra, M. Masellis, H.J. Möller, V. Ozdemir, J. Peuskens, N.R. Schooler, V.M. Steen.12Conference organizers: M. Rietschel, J.L. Kennedy, F. Macciardi, H.Y. Meltzer.23Section Chairs: J.M. Kane and H.Y. Meltzer, J.L. Kennedy and S. Marder, F. Macciardi and M.M. Nöthen, A.G. Awad.3Schizophrenia Research, 1999
- The Arbitrariness of Response Definition in Clinical Trials with AntidepressantsPharmacopsychiatry, 1984
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Coefficient of Agreement for Nominal ScalesEducational and Psychological Measurement, 1960